BioSpace News Archive

- New executive brings strong legal experience serving as General Counsel for biopharmaceutical companies as Edgewise advances clinical muscular dystrophy program -

Enables compliant, timely surveillance and outcomes research to help get safe and effective therapies to patients faster

Schweiger Dermatology Group announced that it has acquired the Harkaway Center for Dermatology and Aesthetics, with locations in Delran and Northfield, New Jersey.

OrthoPediatrics Corp. announced that Mark Throdahl, Chief Executive Officer, Fred Hite, Chief Operating Officer and Chief Financial Officer, and Dave Bailey, President, are scheduled to participate at three upcoming virtual investor conferences in November.

Global Blood Therapeutics, Inc. announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after U.S. financial markets close.

Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020

BioVie Inc. (NASDAQ:BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it will participate in the B. Riley Securities’ Liver Disease Therapeutics Day 2020 on Thursday, October 29, 2020 at 11:00 a.m. ET.

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on November 5, 2020 at 4:30 p.m

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that body composition data from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS),

Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call.